These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 20331626)

  • 21. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.
    Yakes FM; Chinratanalab W; Ritter CA; King W; Seelig S; Arteaga CL
    Cancer Res; 2002 Jul; 62(14):4132-41. PubMed ID: 12124352
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer.
    Gijsen M; King P; Perera T; Parker PJ; Harris AL; Larijani B; Kong A
    PLoS Biol; 2010 Dec; 8(12):e1000563. PubMed ID: 21203579
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells.
    Xia W; Gerard CM; Liu L; Baudson NM; Ory TL; Spector NL
    Oncogene; 2005 Sep; 24(41):6213-21. PubMed ID: 16091755
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The TCF4/β-catenin pathway and chromatin structure cooperate to regulate D-glucuronyl C5-epimerase expression in breast cancer.
    Mostovich LA; Prudnikova TY; Kondratov AG; Gubanova NV; Kharchenko OA; Kutsenko OS; Vavilov PV; Haraldson K; Kashuba VI; Ernberg I; Zabarovsky ER; Grigorieva EV
    Epigenetics; 2012 Aug; 7(8):930-9. PubMed ID: 22805760
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The β-catenin/Tcf4/survivin signaling maintains a less differentiated phenotype and high proliferative capacity of human corneal epithelial progenitor cells.
    Lu R; Bian F; Zhang X; Qi H; Chuang EY; Pflugfelder SC; Li DQ
    Int J Biochem Cell Biol; 2011 May; 43(5):751-9. PubMed ID: 21292023
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Casein kinase 2 (CK2) increases survivin expression via enhanced beta-catenin-T cell factor/lymphoid enhancer binding factor-dependent transcription.
    Tapia JC; Torres VA; Rodriguez DA; Leyton L; Quest AF
    Proc Natl Acad Sci U S A; 2006 Oct; 103(41):15079-84. PubMed ID: 17005722
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor-suppressive effects of psoriasin (S100A7) are mediated through the β-catenin/T cell factor 4 protein pathway in estrogen receptor-positive breast cancer cells.
    Deol YS; Nasser MW; Yu L; Zou X; Ganju RK
    J Biol Chem; 2011 Dec; 286(52):44845-54. PubMed ID: 22016394
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Small molecule antagonists of Tcf4/beta-catenin complex inhibit the growth of HCC cells in vitro and in vivo.
    Wei W; Chua MS; Grepper S; So S
    Int J Cancer; 2010 May; 126(10):2426-36. PubMed ID: 19662654
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interferon-α2b and transforming growth factor-β1 treatments on HCC cell lines: Are Wnt/β-catenin pathway and Smads signaling connected in hepatocellular carcinoma?
    Ceballos MP; Parody JP; Alvarez Mde L; Ingaramo PI; Carnovale CE; Carrillo MC
    Biochem Pharmacol; 2011 Dec; 82(11):1682-91. PubMed ID: 21843516
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth.
    Normanno N; Campiglio M; De LA; Somenzi G; Maiello M; Ciardiello F; Gianni L; Salomon DS; Menard S
    Ann Oncol; 2002 Jan; 13(1):65-72. PubMed ID: 11863114
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trastuzumab signaling in ErbB2-overexpressing inflammatory breast cancer correlates with X-linked inhibitor of apoptosis protein expression.
    Aird KM; Ding X; Baras A; Wei J; Morse MA; Clay T; Lyerly HK; Devi GR
    Mol Cancer Ther; 2008 Jan; 7(1):38-47. PubMed ID: 18202008
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors.
    Chakrabarty A; Bhola NE; Sutton C; Ghosh R; Kuba MG; Dave B; Chang JC; Arteaga CL
    Cancer Res; 2013 Feb; 73(3):1190-200. PubMed ID: 23204226
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential binding of human immunoagents and Herceptin to the ErbB2 receptor.
    Troise F; Cafaro V; Giancola C; D'Alessio G; De Lorenzo C
    FEBS J; 2008 Oct; 275(20):4967-79. PubMed ID: 18795950
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A dynamic exchange of TCF3 and TCF4 transcription factors controls MYC expression in colorectal cancer cells.
    Shah M; Rennoll SA; Raup-Konsavage WM; Yochum GS
    Cell Cycle; 2015; 14(3):323-32. PubMed ID: 25659031
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vivo activity of novel anti-ErbB2 antibody chA21 alone and with Paclitaxel or Trastuzumab in breast and ovarian cancer xenograft models.
    Shen G; Huang H; Zhang A; Zhao T; Hu S; Cheng L; Liu J; Xiao W; Ling B; Wu Q; Song L; Wei W
    Cancer Immunol Immunother; 2011 Mar; 60(3):339-48. PubMed ID: 21086124
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DEAD-box protein p68 is regulated by β-catenin/transcription factor 4 to maintain a positive feedback loop in control of breast cancer progression.
    Guturi KK; Sarkar M; Bhowmik A; Das N; Ghosh MK
    Breast Cancer Res; 2014 Dec; 16(6):496. PubMed ID: 25499975
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Caveolin-1-mediated suppression of cyclooxygenase-2 via a beta-catenin-Tcf/Lef-dependent transcriptional mechanism reduced prostaglandin E2 production and survivin expression.
    Rodriguez DA; Tapia JC; Fernandez JG; Torres VA; Muñoz N; Galleguillos D; Leyton L; Quest AF
    Mol Biol Cell; 2009 Apr; 20(8):2297-310. PubMed ID: 19244345
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SOX9 regulates low density lipoprotein receptor-related protein 6 (LRP6) and T-cell factor 4 (TCF4) expression and Wnt/β-catenin activation in breast cancer.
    Wang H; He L; Ma F; Regan MM; Balk SP; Richardson AL; Yuan X
    J Biol Chem; 2013 Mar; 288(9):6478-87. PubMed ID: 23306204
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improvement of sensitivity to tamoxifen in estrogen receptor-positive and Herceptin-resistant breast cancer cells.
    Chen B; Wang Y; Kane SE; Chen S
    J Mol Endocrinol; 2008 Nov; 41(5):367-77. PubMed ID: 18768663
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EGF prevents the neuroendocrine differentiation of LNCaP cells induced by serum deprivation: the modulator role of PI3K/Akt.
    Martín-Orozco RM; Almaraz-Pro C; Rodríguez-Ubreva FJ; Cortés MA; Ropero S; Colomer R; López-Ruiz P; Colás B
    Neoplasia; 2007 Aug; 9(8):614-24. PubMed ID: 17898861
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.